Aktis Oncology, Inc.

NASDAQ:AKTS

Biotechnology

Healthcare
$16.10 +0.47%

+$0.11 today

Market cap
$865.32M
Beta
1.10
P/E (TTM)
-28.7
EPS (TTM)
-$0.82
52W Low $14.72High $29.16

Volume 0.44M

Average 0.33M

AKTS Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Aktis Oncology, Inc.NASDAQ: AKTS

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures of -$1.85M in Q1 FY2026

Q1 FY2026 capital expenditures was -$1.85M. Over 3 fiscal years it compounded at +60.8% a year.

Context

  • Capital expenditures amounted to 147.5% of revenue in FY2025, down 45.0 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.85M-55.4% QoQ
Last fiscal yearDec 2025
-$9.58M+234.9% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+234.9%——
3-year CAGR+60.8%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(9.58M) USD
Year-over-year change
-234.9%

Capital Expenditures vs competitors

How AKTS compares with its peers on the latest reported figures

  • AKTS's FY2025 capital expenditures of $9.58M is the 2nd largest of the 6 companies compared; the peer median is $1.73M.
  • Its year-over-year change of +234.9% is the highest of 6, against a peer median of -37.7%.
  • Capital expenditures amounts to 147.5% of revenue for AKTS, versus a peer median of 1.1%.
AKTS Competitors Peer median
Capital Expenditures for AKTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMNMImmunome, Inc.LTM Sep 2026$9.67M +36.9%+239.3%—
AKTSAktis Oncology, Inc.FY2025$9.58M +234.9%+60.8%147.5%
IMCRImmunocore Holdings plcLTM Mar 2026$5.82M +15.4%+13.6%1.5%
MGNXMacroGenics, Inc.LTM Mar 2026$1.73M -37.7%-19.2%1.1%
AURAAura Biosciences, Inc.LTM Mar 2026$362K -73.2%-25.8%—
BCYCBicycle Therapeutics plcLTM Mar 2026$106.68K -94.2%-50.1%0.2%
Peer median (excluding AKTS) $1.73M-37.7%-19.2%1.1%

Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.93M)(28.64M)(43.98M)(63.73M)
Depreciation & Amortization445K1.12M1.58M2.33M
Deferred Income Tax0000
Stock-Based Compensation698K1.48M2.26M5.13M
Change in Working Capital(1.14M)(15K)58.98M(3.23M)
Accounts Receivables0(257K)(861K)1.03M
Inventory0000
Accounts Payables(1K)659K360K(44K)
Other Working Capital(1.14M)(417K)59.48M(4.22M)
Other Non-Cash Items(200K)(3.95M)(4.07M)(4.62M)
Operating Cash Flow(18.13M)(30M)14.76M(64.13M)
Capital Expenditures(2.31M)(3.76M)(2.86M)(9.58M)
Acquisitions (Net)0000
Purchases of Investments0(145.81M)(288.4M)(193.87M)
Sales of Investments080.69M100.86M269.42M
Other Investing Activities057K00
Investing Cash Flow(2.31M)(68.83M)(190.4M)65.96M
Debt Repayment0000
Common Stock Issued000336K
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(151K)0(1.72M)(1.55M)
Financing Cash Flow119.98M0183.28M(1.21M)
Effect of Forex Changes0000
Net Change in Cash99.55M(98.83M)7.65M625K
Free Cash Flow(20.43M)(33.77M)11.9M(73.71M)

Aktis Oncology, Inc.

NASDAQ:AKTS

Intrinsic Alpha fair value

Locked

Current Price

$16.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.